Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
VEGFR

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

VEGFR

Chemical Structure Cat. No. Product Name CAS No.
SAR131675 Chemical Structure
 BCP35024 SAR131675 1433953-83-3
SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
(Z)-Guggulsterone Chemical Structure
 BCP07472 (Z)-Guggulsterone 39025-23-5
Z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis.
5Z-7-Oxozeaenol Chemical Structure
 BCP34467 5Z-7-Oxozeaenol 253863-19-3
5Z-7-Oxozeaenol is a covalent inhibitor that acts against the several protein kinases (e.g. ERK2 and TAK1) that possess a free cysteine at the gatekeeper-2 position.
Donafenib Chemical Structure
 BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
TAS-115 mesylate Chemical Structure
 BCP34015 TAS-115 mesylate 1688673-09-7
TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
TAS-115 Chemical Structure
 BCP34014 TAS-115 1190836-34-0
TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
SU 5205 Chemical Structure
 BCP25520 SU 5205 3476-86-6
SU 5205 is a VEGFR2 inhibitor.
Vandetanib trifluoroacetate Chemical Structure
 BCP33121 Vandetanib trifluoroacetate 338992-53-3
Vandetanib trifluoroacetate is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
PTC299 Chemical Structure
 BCP32869 PTC299 1256565-36-2
PTC299 is a potent, orally bioavailable VEGFA inhibitor, targets dihydroorotate dehydrogenase (DHODH), resulting in cell growth inhibition and differentiation in leukemias, including acute myeloid leukemia, linking DHODH regulation and stress-induced VEGFA and angiogenesis.
hVEGF-IN-1 Chemical Structure
 BCP32794 hVEGF-IN-1 1637443-98-1
hVEGF-IN-1 represses human VEGF-A translation and shows antitumor activity.
123下一页末页共 128 条记录 1 / 13 页 
0086-15971444841